The company's lead compound, formulated as a topical eye drop, has shown promise in treating AMD and DR by penetrating all the way back to the retina without any toxic effects. This could potentially reduce and prevent vision loss caused by these diseases, which are leading causes of blindness in developed countries. OcuCure's approach has been validated in human tissues, confirming its ability to target ocular angiogenesis. Unlike currently available drugs that require monthly injections into the eye, OcuCure's eye drops offer a more convenient and potentially effective treatment option.